Navigation Links
Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
Date:1/8/2008

Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Exe
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... CGM System as a non-invasive, wireless continuous glucose ... Doman , Executive Chairman and Interim CEO of ... Capital Markets, Tenth Annual Equity Conference. ... to prospective corporate partners and investors at 9:00 ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ... rapid growth of these markets. The ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ... Summary,Although the past decade has seen the ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... May 24, 2011 Reportlinker.com announces that ... in its catalogue: Pharmaceuticals ... Report (Global) http://www.reportlinker.com/p0503954/Pharmaceuticals-Industry-Report---Top-500-Pharmaceuticals-Industry-Report-Global.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu ... Report Plimsoll Publishing Ltd. ...
... Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ... Patou, M.D., chief medical officer, is scheduled to present at ... on Wednesday, May 25, 2011 at noon BST. Dr. Patou ... A live audio webcast of Pacira,s presentation can ...
Cached Medicine Technology:Reportlinker Adds Pharmaceuticals Industry Report - Top 500 Pharmaceuticals Industry Report (Global) 2Reportlinker Adds Pharmaceuticals Industry Report - Top 500 Pharmaceuticals Industry Report (Global) 3Reportlinker Adds Pharmaceuticals Industry Report - Top 500 Pharmaceuticals Industry Report (Global) 4Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... 10 Once-daily Keppra XR(TM) (levetiracetam) extended-release tablets ... mg--enabling doctors to simplify patients, treatment plans by ... day. (Photo: http://www.newscom.com/cgi-bin/prnh/20090410/NY97244 )According to ... and Neurology , patients are more likely ...
... embracing new ways of communicating the latest aesthetic enhancement options by turning ... ... (Vocus) April 10, 2009 -- The founder and director of the Arizona ... exploring new and innovative ways of reaching out to patients in the ...
... The Sutter Health network of doctors, hospitals and ... for 2008. Sutter Health,s combined 2008 systemwide income from ... other services was $463 million, compared to $471 million ... $277 million in investment income and changes in net ...
... one of 14 given recent warning, will remain on the ... Bowing to the pleas of hospice experts, the U.S. Food ... from the market an unapproved liquid morphine painkiller given to ... the FDA,s Center for Drug Evaluation and Research, told the ...
... MISSION VIEJO, Calif., April 9 The Ensign Group, ... its Mt. Ogden Health & Rehabilitation Center in Ogden, ... and Medicaid Services, Special Focus Facility program.(Logo: ... small part of what we,re accomplishing as we strive ...
... NEW YORK (April 9, 2009) -- A newly discovered gene ... according to a study by researchers at Weill Cornell Medical ... Cancer Research , may lead to more accurate tests ... different type of fusion than researchers have found in cancer ...
Cached Medicine News:Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 2Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 3Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 4Health News:Scottsdale, Arizona Cosmetic Plastic Surgeon Reaches Out to Patients with State-of-the-Art New Website 2Health News:Scottsdale, Arizona Cosmetic Plastic Surgeon Reaches Out to Patients with State-of-the-Art New Website 3Health News:Sutter Health Announces 2008 Financial Performance 2Health News:Sutter Health Announces 2008 Financial Performance 3Health News:FDA Reverses Stance on Removal of Morphine Painkiller 2Health News:The Ensign Group Successfully Graduates Third Nursing Home From CMS Special Focus Program 2Health News:Gene fusion discovery may lead to improved prostate cancer test 2
... up to 10 LPM of oxygen reducing the ... The M10 is engineered to reduce the cost ... has fewer parts than any other concentrator on ... help you to reduce expenditure on accessories and ...
... important to have a choice that fits your ... with innovative excellence, offers two great choices! Introducing ... value packed conservers., ,With its single AA ... hours a day for 3 to 4 weeks ...
... Get the equivalent of 7.5 liters out ... will you need two machines for your high-flow ... OXYMIZER Disposable Oxygen-Conserving Devices function like standard conservers, ... flow of oxygen required to saturate a patient. ...
The 24-Hour Oxygen Conserver....
Medicine Products: